Loreline Study: Characterization of Long Responders Under Eribuline

Breast Cancer Patients Clinical Trial

— Loreline  

Official title:

National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03771183
• Other study ID #: 2018-A03054-51
• Status: Completed
• Start date: August 23, 2019
• Est. completion date: February 28, 2021

Study information

• Verified date: April 2021
• Source: Centre Jean Perrin
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

There is currently no strict recommendations for the management of patients who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy for advanced breast cancer. However, Halaven® can represent a therapeutic alternative at this stage of the disease. Indeed, since march 2011, Halaven® has been granted Marketing Authorization (MA) for patients with metastatic or locally advanced breast cancer, whose disease has progressed after at least two lines of chemotherapy for advanced disease (3rd line). In these patients, the indication for marketing authorization specifies that the previous treatment must have included an anthracycline and a taxane except in patients who can not receive these treatments. An extension of indication was obtained on 27/06/2014 with a marketing authorization obtained in the treatment of locally advanced or second-line metastatic breast cancer. According to the Transparency Commission of the High Authority of Health (HAS dated September 23, 2015), Halaven® (Eribulin), administered as monotherapy, in the third line of treatment and beyond, represents a therapeutic option, because it brings an improvement of medical service rendered compared to Capecitabine (XELODA®) and Vinorelbine (NAVELBINE®). In addition, Halaven® (Eribuline) administrated as monotherapy in second-line of treatment is an alternative to other monotherapies recommended for the treatment of locally advanced or metastatic relapsed breast cancer, such as Capecitabine (XELODA®). and Vinorelbine (NAVELBINE®). But, no improvement of medical service rendered has been reported in second line of treatment. According to these results, it would be interesting to have additional data concerning the use of Halaven® (Eribulin), in the second and third lines, but also in the fourth line. For this purpose, the investigators propose to perform a study in patients with metastatic breast cancer who have failed treatment after the first line and beyond. In this study, the investigators will be particularly interested in "long-responder" patients, that is to say, in objective response or with stability for 6 months or more under Halaven®, in order to better characterize these patients. Patients must have been treated by Halaven between September 2011 and December 2016, to have a sufficient follow-up for the survival data of the patients.

Description:

The investigators will perform a cross-sectional study in patients with metastatic breast cancer who have failed treatment after the first line and beyond. In this study, the investigators will be particularly interested in "long-responder" patients, that is to say, in objective response or with stability for 6 months or more under Halaven®, in order to better characterize these patients. Patients must have been treated by Halaven between September 2011 (the year of obtaining the MA in the 3rd line of treatment) and December 2016, to have a sufficient follow-up for the survival data of the patients. The investigators will also focus on patients with liver metastases because there is limited data in this population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: February 28, 2021
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Women aged between 18 and 75 years
• Metastatic breast cancer patient
• Patients treated by Halaven® in second, third or fourth line of treatment for their metastatic breast cancer
• Halaven® treatment must have been received between September 2011 and December 2016
• Patients responding or in stability during at least 6 months under Halaven® treatment
• Patients pretreated by at least one line of any other chemotherapy
• Non opposition form dated and signed by the investigator (attesting that the patient consented orally that clinical, biological and imaging data concerning her were analyzed in this study)

Exclusion Criteria:

• Male
• Patient with cognitive and psychiatric disorders
• Patient deprived of liberty by judicial or administrative decision
• Insufficient knowledge or understanding of the French language which does not allow for the non-opposition form to be understood

Related Conditions & MeSH terms

• Breast Cancer Patients
• Breast Neoplasms
• Therapy Related Tumor

Intervention

Other:
• Patients in long response during Halaven® treatment
Data collection

Locations

Country	Name	City	State
France	CHRU Jean Minoz	Besançon
France	Centre Jean Perrin	Clermont-Ferrand
France	Institut de Cancérologie Lucien Neuwirth	Saint Priest en Jarez
France	Centre Paul Strauss	Strasbourg
France	Institut de Cancérologie de Lorraine	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Centre Jean Perrin

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure patient's age at the beginning of Halaven® treatment in patients who received Halaven® and who were in response since 6 months or more	-patient's age at the beginning of Halaven® treatment	up to at least 6 months after Halaven® start
Primary	Characterize tumor of patients who received Halaven® and who were in response since 6 months or more	histological tumoral type	up to at least 6 months after Halaven® start
Primary	Characterize patients who received Halaven® and who were in response since 6 months or more, according to previous treatments (neoadjuvant and/or adjuvant treatments)	number of patients who have received neoadjuvant treatments number of patients who have received adjuvant treatments	up to at least 6 months after Halaven® start
Primary	Characterize patients who received Halaven® and who were in response since 6 months or more, according to the number of lines of treatment received for metastatic disease	-number of lines of treatment received for metastatic disease, including treatment received before Halaven®	up to at least 6 months after Halaven® start
Primary	Characterize metastatic localizations of patients who received Halaven® and who were in response since 6 months or more	number of patients with metastatic localizations	up to at least 6 months after Halaven® start
Primary	Characterize patients who received Halaven® and who were in response since 6 months or more	number of patients with liver metastasis, surgery of liver metastasis	up to at least 6 months after Halaven® start
Primary	Measure the number of Halaven® injections to obtaine the "best" response in patients who received Halaven® and who were in response since 6 months or more	-number of Halaven® injections until the " best " response is obtained	up to at least 6 months after Halaven® start
Primary	Measure the best response under Halaven® in patients who received Halaven® and who were in response since 6 months or more	-duration of the " best " response under Halaven® (in months)	up to at least 6 months after Halaven® start
Primary	Measure hormonal receptors tumours of patients who received Halaven® and who were in response since 6 months or more	hormonal receptors of primitive tumor (percentage of stained cells)	up to at least 6 months after Halaven® start
Primary	Measure KI-67 tumours of patients who received Halaven® and who were in response since 6 months or more	-pathology of primitive cancer : ki-67	up to at least 6 months after Halaven® start
Primary	Measure Scarff Bloom Richardson grade tumours of patients who received Halaven® and who were in response since 6 months or more	-pathology of primitive cancer : Scarff Bloom Richardson grade The Scarff Bloom Richardson garde will be measured with a scale from I to III. A grade III represent a worse outcome.	up to at least 6 months after Halaven® start
Secondary	Measure Percentage of long responders patients under Halaven® among patients treated by Halaven® in second, third and fourth line of treatment	Percentage of patients in objective response or in stability during 6 months and more since the beginning of Halaven® treatment among all patients treated by Halaven® (in second, third and fourth line of treatment). This percentage will be collected in each participating center at the end of the study.	up to at least 6 months after Halaven® start
Secondary	-Evaluate the percentage of patients with hepatic metastases	-Percentage of liver metastatic patients	up to at least 6 months after Halaven® start
Secondary	-Evaluate the specific response and/or stability in patients with hepatic metastases, that is measure percentage of liver metastatic patients in complete or partial response or in stability under Halaven®	-Percentage of liver metastatic patients in complete or partial response or in stability under Halaven®	up to at least 6 months after Halaven® start
Secondary	-Evaluate toxicities due to the use of Halaven®	Number and percentage of patients who have a grade 3 and a grade 4 toxicity (for each toxicity reported); -Collection of toxicities under Halaven® Toxicities considered are toxicities grade 3, 4 and 5 (CTCAE V4.03 dated on june 14, 2010) : nausea, vomiting,diarrhea, neutropenia, anemia, leucopenia, fatigue, peripheral neuropathy, alopecia, loss of apetite. If others toxicities appear, they will be notified in the e-CRF.	up to at least 6 months after Halaven® start
Secondary	-Evaluation of percentage of patients in complete or partial response or in stability under Halaven® according to number of previous metastatic treatment lines	-Percentage of patients in complete or partial reponse or in stability under Halaven®. This percentage will be calculated in patients treated by Halaven® in second, third or fourth line of treatment	up to at least 6 months after Halaven® start
Secondary	-Evaluation of Progression Free Survival (PFS)	-Measure of time to progression (in months or in years) The PFS will be calculated from date of Halaven start to first progression date whatever the type of progression (local progression, progression of a previous metastasis and/or appearance of new metastasis, and/or new cancer).	up to at least 6 months after Halaven® start
Secondary	Evaluation of overall survival	Measure of overall survival (in months or in years) Overall survival calculated from start of Halaven to death, whatever the cause, or date of last consultation if patients are alive at the 12/31/2017.	up to at least 6 months after Halaven® start